IMMUNE PHARMACEUTICALS, INC.

(IMNPQ)
Delayed OTC Markets  -  05/20 09:30:19 am EDT
0.001000 USD    0.00%
2021IMMUNE PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Change in Directors or Principal Officers, Other Events (form 8-K)
AQ
2021IMMUNE PHARMACEUTICALS INC : Change in Directors or Principal Officers, Other Events (form 8-K)
AQ
2020Motion for Asset Sale Approved for Immune Pharmaceuticals, Inc.
CI
SummaryQuotesChartsNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

IMMUNE PHARMACEUTICALS INC : Change in Directors or Principal Officers, Other Events (form 8-K)

04/12/2021 | 08:09am EDT

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;

           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers



On April 12, 2021, Adeel Ahmed-Daudpota, age 34, has been appointed as the President and Interim Chief Executive Officer of the Immune Pharmaceuticals to fill the vacancy that resulted from the company entering into chapter 7.

Mr. Ahmed-Daudpota is an investment banker, predominantly specializing in M&A, restructurings, and Special Situations. In connection with his appointment to the board of Immune Pharmaceuticals as Interim CEO, Mr Daudpota's role Will entail providing the company's shareholders options to continue trading and for identifying and merging with another viable pharmaceutical business.

The appointment as such carries no compensation and does not cover any expenses. This is subject to change post-merger.

The proposed merger is intended to protect existing shareholder interest and provide a private pharmaceutical company a public company and large shareholder base to raise additional capital.



  - 2 -


Item 8.01. Other Events



Mr Daudpota effective immediately upon appointment shall be responsible for updating the company's filings to bring the company up to date with its regulatory requirements, In addition Mr. Daudpota is responsible for providing a viable merger candidate and overseeing the merger with a new entity.

Mr Daudpota hereby notifies the market that a merger is expected to take place within the coming weeks that will ensure the common stock holders will be protected from discontinuation of trading or loss of public equity.

Mr Daudpota has secured the full support of United General LTD a UK investment firm and liquidity provider, Where he also he holds a board position.

The proposed merger plan will separate the Immune Pharmaceuticals LLC (In chapter 7) into the surviving entity that will not be subject to chapter 7 bankruptcy.

Holders of common stock under this structure will retain a shareholding in the surviving public company and will be afforded as such shareholder rights in the new operating pharmaceutical company post-merger.

Upon completion of the merger, we will appoint a new board and apply to have the bankruptcy status lifted from Finra.

- 3 -

© Edgar Online, source Glimpses

All news about IMMUNE PHARMACEUTICALS, INC.
2021IMMUNE PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Change in..
AQ
2021IMMUNE PHARMACEUTICALS INC : Change in Directors or Principal Officers, Other Events (form..
AQ
2020Motion for Asset Sale Approved for Immune Pharmaceuticals, Inc.
CI
2020Motion For Case Conversion Approved for Immune Pharmaceuticals, Inc.
CI
2019Motion for Asset Sale Approved for Immune Pharmaceuticals, Inc.
CI
2019Immune Pharmaceuticals, Inc. cancelled the transaction announced on October 9, 2018
CI
2019Motion for Case Conversion or Dismissal Filed for Immune Pharmaceuticals, Inc.
CI
2019Bidding Procedure Approved for Immune Pharmaceuticals, Inc.
CI
2019Motion for Asset Sale Filed by Immune Pharmaceuticals, Inc.
CI
2019Motion for Case Conversion Filed by Immune Pharmaceuticals, Inc.
CI
More news
Chart IMMUNE PHARMACEUTICALS, INC.
Duration : Period :
Immune Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Adeel Ahmed-Daudpota President & Chief Executive Officer
Devin J. Shaw Chief Financial Officer
John Zhang Vice President-Research & Development
John A. Neczesny Independent Director
Jeffrey Paley Independent Director
Sector and Competitors
1st jan.Capi. (M$)
IMMUNE PHARMACEUTICALS, INC.-23.08%0
JOHNSON & JOHNSON6.04%477 336
PFIZER, INC.-9.55%299 678
ROCHE HOLDING AG-12.57%281 309
ELI LILLY AND COMPANY10.77%275 413
ABBVIE INC.10.13%263 494